D. Boral Capital upgraded Artelo Biosciences, Inc. ARTL on Tuesday.The analyst upgraded from Hold to Buy and introduced a price forecast of $20.Analyst Jason Kolbert wrote, “We continue to view Artelo as an emerging biotechnology company focused on Cachexia and chemotherapy-induced peripheral neuropathy (CIN) with the lead program.”ART27.13 is a Phase 2 asset, a selective benzimadazole agonist acquired from AstraZeneca Plc AZN.The analyst wrote that ART27.13 showed potential to stimulate appetite and promot ...